On May 5, 2025, OmniAb, Inc. announced a co-discovery alliance with VERAXA Biotech AG for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors. This collaboration combines OmniAb’s transgenic antibody discovery solutions with VERAXA’s proprietary ADC linker technology and conjugation expertise.
Under the terms of the agreement, VERAXA will initiate a bsADC program addressing two target molecules in cancer medicine, utilizing OmniAb's platforms to source high-quality human antibody leads. The resulting bsADC program will be jointly owned by both parties.
Both OmniAb and VERAXA will share any future revenues derived from the program’s continued development, licensing, and commercialization. This partnership expands OmniAb's pipeline into a growing therapeutic area and validates its technology platform through a strategic collaboration.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.